FK633: A potent and selective platelet GPIIb/IIIa antagonist

Cardiovascular Drug Reviews

Volumn 17, Issue 2, 1999, Pages 147-159

  Aoki, Toshiaki ^b   Harada, Kayoko ^c   Seki, Jiro ^c   Tanaka, Akito ^a   Takasugi, Hisashi ^a   Motoyama, Yukio ^c  

^a Chemical Research Laboratories   (Japan)

^b ASTELLAS PHARMA INC   (Japan)

^c NONE

Author keywords

Antiplatelet drugs; FK633; GPIIb IIIa antagonists; Thrombosis

Indexed keywords

3 [[4 [[4 (AMINOIMINOMETHYL)PHENYL]AMINO] 1,4 DIOXOBUTYL]AMINO] 4 PENTYNOIC ACID; 4 (4 AMIDINOPHENOXY)BUTYRYLASPARTYLVALINE; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; COLLAGEN; FIBRINOGEN RECEPTOR ANTAGONIST; LAMIFIBAN; TIROFIBAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; BLEEDING; DOG; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RESTENOSIS; REVIEW; THROMBOCYTE AGGREGATION; THROMBOSIS;

EID: 0032826585     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.1999.tb00010.x     Document Type: Review

References (53)

1. Aguirre FV, Topol EJ, Ferguson JJ, et al., for the EPIC Investigators. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. Circulation 1995;91:2882-2890.
2. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy - I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
3. Aoki T, Cox D, Senzaki K, et al. The anti-platelet and anti-thrombotic effects of FK633, a peptide mimetic GPIIb/IIIa antagonist. Thromb Res 1996;81:439-450.
4. Aoki T, Cox D, Senzaki K, et al. Comparison of the antithrombotic effects of FK633, GPIIb/IIIa antagonist, and aspirin in a guinea pig thrombosis model. Thromb Res 1998;89:129-136.
5. Aoki T, Senzaki K, Honda S, et al. FR189419 is a novel αIIbβ3 antagonist with a minimum adverse effect on bleeding time. (Abstract). Thromb Haemost 1997;78(suppl):666.
6. 2 synthesis. Thromb Haemost 1998;79:1184-1190.
7. Asada Y, Hara S, Tsuneyoshi A, et al. Fibrin-rich and platelet-rich thrombus formation on neointima: recombinant tissue factor pathway inhibitor prevents fibrin formation and neointimal development following repeated balloon injury of rabbit aorta. Thromb Haemost 1998;80:506-511.
8. Bednar B, Bednar RA, Cook JJ, et al. Drug-dependent antibodies against GPIIb/IIIa induced thrombocytopenia (Abstract). Circulation 1996;94(suppl I):I-99.
9. Berkowitz SD, Sane DC, Sigmon KN, et al. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the prevention of ischemic complications (EPIC) study group. J Am Coll Cardiol 1998;32:311-319.
10. Byzova TV, Rabbani R, D'Souza SE, Plow EF. Role of integrin αvβ3 in vascular biology. Thromb Haemost 1998;80:726-734.
11. Cines DB. Glycoprotein IIb/IIIa antagonists: potential induction and detection of drug-dependent antiplatelet antibodies. Am Heart J 1998;135:S152-S159.
12. Collar BS, Anderson K, Weisman HF. New antiplatelet agents: platelet GPIIb/IIIa antagonists. Thromb Haemost 1995;74:302-308.
13. Cook NS, Kottirsch G, Zerwes HG. Platelet glycoprotein IIb/IIIa antagonist. Drugs Fut 1994;19:135-159.
14. Cox D, Aoki T, Motoyama Y, Seki J, Yoshida K. The pharmacology of integrins. Med Res Rev 1994;14: 195-228.
15. Cox D, Motoyama Y, Seki J, Aoki T, Dohi M, Yoshida K. Pentamidine: a nonpeptide GPIIb/IIIa antagonist - in vitro studies on platelets from humans and other species. Thromb Haemost 1992;68:731-736.
16. Davies MJ. A macro and micro view of coronary vascular insult in ischemic heart disease. Circulation 1990;82(suppl II):1138-1146.
17. Eliceiri BP, Klemke R, Stromblad S, Cheresh DA. Integrin αβ3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis. J Cell Biol 1998;140:1255-1263.
18. Engleman VW, Nickols GA, Ross FP, et al. A peptidomimetic antagonist of the integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. J Clin Invest 1997;99:2284-2292.
19. Ferrari E, Thiry M, Touati C, Gibelin P, Baudouy M. Acute profound thrombocytopenia after c7E3 Fab therapy. Circulation 1997;96:3809-3810.
20. Fitzgerald DJ, Roy L, Catella F, Fitzgerald GA. Platelet activation in unstable coronary disease. N Engl J Med 1986;315:983-989.
21. Frelinger AL III, Cohen I, Plow EF, et al. Selective inhibition of integrin function by antibodies specific for ligand occupied receptor conformers αIIbβ3. J Biol Chem 1990;265:6346-6352.
22. Frelinger AL III, Lam SC-T, Plow EF, Smith MA, Loftus JC, Ginsberg MH. Occupancy of an adhesive glycoprotein receptor modulates expression of an antigenic site involved in cell adhesion. J Biol Chem 1988;263:12397-12402.
23. Fuster V. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation 1994;90:2126-2148.
24. Hartman GD. Tirofiban hydrochloride. Drugs Fut 1995;20:897-901.
25. Hoekstra WJ, Poulter BL. Combinatorial chemistry techniques applied to nonpeptide integrin antagonists. Curr Med Chem 1998;5:195-204.
26. 2+ signaling. Blood 1998;92:3675-3683.
27. Honda S, Tomiyama Y, Pelletier AJ, et al. Topography of ligand-induced binding sites, inducing a novel cation-sensitive epitope (AP-5) at the amino terminus of the human integrin β3 subunit. J Biol Chem 1995;270:11947-11954.
28. Kaida T, Matsuno H, Kozawa O, Miyata H, Uematsu T. Antiplatelet effect of FK633, a platelet glycoprotein IIb/IIIa antagonist, on thrombus formation and vascular patency after thrombolysis in the injured hamster carotid artery. Thromb Haemost 1997;77:562-567.
29. Kouns WC, Wall CD, White MM, Fox CF, Jennings LK. A conformation-dependent epitope of human platelet glycoprotein IIIa. J Biol Chem 1990;265:20594-20601.
30. Matsuno H, Kozawa O, Niwa M, Kaida T, Hayashi H, Uematsu T. GR144053, a fibrinogen receptor antagonist, enhances the suppression of neointima formation by losartan, an angiotensin II receptor antagonist, in the injured carotid artery of hamster. Br J Pharmacol 1997;122:1099-1104.
31. Matsuno H, Stassen JM, Vermylen J, Deckmyn H. Inhibition of integrin function by a cyclic RGD-containing peplide prevents neointima formation. Circulation 1994;90:2203-2206.
32. Nicholson NS, Panzer-Knodle SG, Salyers AK, et al. SC-54684: an orally active inhibitor of platelet aggregation. Circulation 1995;91:403-410.
33. O'Brien J. Effects of salicylates on human platelets. Lancet 1986;1:779-783.
34. Olson RW, Dotson R, Mathis J, Cohen DS, Webb RL. Beneficial effects of combined thromboxane synthase inhibition/receptor blockade with CGS22652 in a canine model of thrombosis. Eur J Pharmacol 1993;236: 75-87.
35. Prager NA, Torr-Bron SR, Sobel BE, Abendschein DR. Maintenance of patency after thrombolysis in stenotic coronary arteries requires combined inhibition of thrombin and platelets. J Am Coll Cardiol 1993;22:296-301.
36. 2 formation during coronary thrombolysis. J Pharmacol Exp Ther 1997;281:1178-1185.
37. Rubenstein MD, Wall RT, Bain DS, Harrison DC. Platelet activation in clinical coronary artery disease and spasm. Am Heart J 1981;102:363-367.
38. Ruggeri ZM. Mew insights into the mechanisms of platelet adhesion and aggregation. Semin Hematol 1994;31:229-239.
39. Saltiel E, Ward A. Ticlopidine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutical efficacy in platelet dependent disease states. Drugs 1987;34:222-262.
40. Salvioni A, Galli S, Lauri G, Perego GB, Assanelli E, Guazzi MD. Thrombin activation and late restenosis after percutaneous transluminal coronary angioplasty. Am Heart J 1998:135:503-509.
41. Simpfendorfer C, Kottke-Marehant K, Lowrie M, et al. First chronic platelet glycoprotein IIb/IIIa integrin blockade. A randomized, placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions. Circulation 1997;96:76-80.
42. Smith JW, Ruggeri ZM, Kunicki TJ, et al. Interaction of integrins αvβ3 and glycoprotein IIb/IIIa with fibrinogen. J Biol Chem 1990;265:12267-12271.
43. Suzuku K, Sakai Y, Hisamichi N, et al. Comparison of the antiplatelet effect of YM337 and abciximab in rhesus monkeys. Eur J Pharmacol 1997;336:169-176.
44. Tanaka A, Sakai H, Ishikawa T, Aoki T, Motoyama Y, Takasugi H. Design, synthesis, and evaluation of orally active fibrinogen inhibitors. Bioorg Med Chem Lett 1997;7:521-526.
45. Tanaka A, Sakai H, Ishikawa T, et al. Design, synthesis, and evaluation of fibrinogen inhibitors, ω-(p-amininophenoxy)alkanoylaspartic acid derivatives. Bioorg Med Chem Lett 1996;6:1443-1448.
46. Tanaka A, Sakai H, Ishikawa T, et al. Rational drug design of the fibrinogen inhibitors FK633 and FR158999. Drugs Fut 1998;23:291-299.
47. Tcheng JE, Harrington RA, Kottke-Marehant K, et al. IMPACT Investigators. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integretin in elective coronary intervention. Circulation 1995;91:2151-2157.
48. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. N Engl J Med 1994;330:956-961.
49. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Randomized efficacy study of tirofiban for outcomes and restenosis. Circulation 1997;96:1445-1453.
50. Theroux P, Kou S, Roy L, et al., on behalf of the investigators. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. The Canadian Lamifiban Study. Circulation 1996;94:899-905.
51. Topol EJ, Califf RM, Weismann HE, et al., on behalf of the EPIC investigators. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994;343:881-886.
52. Tschopp JF, Mazur C, Gould K, Connolly R, Pierschbacher MD. Inhibition of thrombosis by a selective fibrinogen receptor antagonist without effect on bleeding time. Thromb Haemost 1994;72:119-124.
53. Willerson JT, Hillis LD, Winniford M, Buja LM. Speculation regarding mechanisms responsible for acute ischemic heart disease syndromes. J Am Coll Cardiol 1986;8:245-250.